Checkerboard immunoblotting, a versatile new technique for examining multiple antigen and antibody interactions simultaneously, was applied in studies of epitopes in the cholera enterotoxin (CT)-related heat-labile enterotoxin (LT) family. The purified antigens used included the following: the B-subunit proteins from two CTs (CT-B-1 and CT-B-2), from classical and El Tor biotype strains of Vibrio cholerae, respectively; human LT-B-1 (H-LT-B-1) and porcine LT-B (P-LT-B) derived from LTs produced by Escherichia coli strains of human (H) and porcine (P) origins, respectively; and genetically engineered chimeric P-LT-Bs with amino acid substitutions from H-LT-B-1. The antigens were used in native, partially denatured, and CNBrfragmented forms. The antisera included a variety of mouse monoclonal antibodies against these proteins as well as polyclonal hyperimmune sera and sera from adult American volunteer vaccinees or convalescents from induced cholera. Rabbit antisera against synthetic peptides of the CT-B-1 subunit were also used. In some instances, the effect of GM, ganglioside on antibody binding was evaluated. The reactivity of the monoclonal antibodies was directed primarily against conformational epitopes: some were specific for homologous antigen; some were promiscuously reactive; and some recognized particular related proteins. Individual amino acids (most notably amino acid 46) exerted a dominant effect on epitope formation-in some instances, in a complementary fashion. Epitope expression was also affected by distant amino acid residues (polar effects). Some reactions were blocked by GM, treatment of the immobilized antigen, indicating that the epitope was involved in or affected by GM, binding. Polyclonal antibody responses varied within and among animal species.
Despite intensive efforts over the past decades, an effective and economical vaccine against cholera remains to be developed and deployed (for reviews, see references 3, 4, and 10). With the recognition that cholera is a toxin-mediated disease, hopes were raised that, as with tetanus and diphtheria, a toxoid vaccine would be an effective prophylactic. Indeed, numerous laboratory studies supported the concept that antitoxic immunity could protect against experimental cholera. However, results of field trials of various toxoid vaccines were disappointing, at best. Because of (i) the demonstrated failure of parenterally administered killed whole-cell bacterins to provide significant and lasting protection, especially in children-the target population in endemic or epidemic areas; (ii) the failure of parenterally administered toxoids to provide effective and enduring immunity; and (iii) the recognition that the disease itself is an immunizing process, attention has shifted almost entirely to orally administered antigens to stimulate mucosal immune responses. These have been either living attenuated mutants of Vibrio cholerae or cocktails consisting of large amounts of killed cells mixed with the B-subunit protein of the cholera enterotoxin (CT).
CT was first isolated to homogeneity a little over 20 years ago (6) from supernatants of cultures of classical biotype Inaba serotype V. cholerae 569B. Because of its hypertoxigenicity in comparison with other strains of V. cholerae, * Corresponding author. strain 569B Inaba has been used exclusively for the production of the cholera toxoids which have been used in the field studies alluded to above. In 1974, it was recognized that CT produced by El Tor biotype Ogawa serotype V. cholerae 3083 differed immunologically from the CT which had been isolated earlier from strain 569B Inaba (7) . That the immunologic differences between 569B CT (CT-1) and CT from strain 3083 (CT-2) could be meaningful was later demonstrated by Marchlewicz and Finkelstein (13) , who showed that various polyclonal antisera raised against CT-1 antigens neutralized CT-2 considerably less effectively than they neutralized the homologous toxin. In that study, which included CT-related heat-labile enterotoxins (LTs) from Escherichia coli strains of human (H) and porcine (P) origin, it was also pointed out that "enterotoxin-type specific antibodies, in some instances, account(ed) for a major portion of the neutralizing activity (of the hyperimmune sera used)" (13) .
We suggest that part of the reason for the failure of cholera toxoids in previous field trials may reside in the fact that CT-1 antigen was used against the prevailing epitype of CT, which was primarily CT-2 (R. A. Finkelstein (CT-1 and CT-2) , H-LT-1, P-LT, chimeras (pDL-2, pDL-3, pDL-5, and pDL-7) and synthetic peptides (CT-P1 through CT-P7). *, The validity of Asn-22 and Asn-70, originally defined by amino acid sequencing, has been questioned (16) . cholerae was less than that attained with classical biotype strains which were present simultaneously.
In this study, we extended our previous observations (5) on the similarities and differences in the CT-related family of enterotoxins by using a new technique, which we call checkerboard immunoblotting (CBIB) (9a) . CBIB facilitates the examination of multiple antigen and antibody interactions conveniently and reproducibly with minimal amounts of reactants. Reactions of numerous combinations of CTrelated antigens and antibodies were examined to identify the type, possible location, and role of selected amino acid residues in the formation of different epitopes.
MATERIALS AND METHODS
Chemicals and reagents. Urea, nitrocellulose membranes, 2-mercaptoethanol (2-ME), and other reagents for the immunoassay were from Bio-Rad Laboratories (Richmond, Calif. Antigens. The antigens used in this study were, primarily as described previously (5, 12) , the purified B-subunit proteins of CT-1 and CT-2, human LT-1 (H-LT-1), porcine LT (P-LT), and genetically engineered chimeric proteins, pDL-2 (P-LT-B in which its Lys-102 was substituted with H-LT-B Glu-102), pDL-3 (P-LT-B with H-LT-B and CT-B Ala-46 and H-LT-B Glu-102), pDL-5 (P-LT-B with H-LT-B and CT-B Ala-46), and pDL-7 (P-LT-B with H-LT-B Ser-4 and H-LT-B-1 and CT-B-1 His-13) (5, 12) . (By using the single letter amino acid code, pDL-2, pDL-3, pDL-5, and pDL-7 could be designated P-LT-B/Ki02E, P-LT-B/KiO2E and E46A, P-LT-B/E46A, and P-LT-B/T4S and R13H, respectively.) Amino acid sequences of the proteins used are summarized in Fig. 1 . Antigens were applied in the native state, or as denatured (8 M urea), CNBr-digested, or heated and/or reduced (5% 2-ME) forms. CNBr digestion of antigens was performed as follows: proteins (0.5 ,umol) were solubilized in 1 ml of 0.18 M Tris buffer (pH 8.5) containing 8 M urea and 5 mM EDTA, reduced (70 mM 2-ME), carboxymethylated (80 mM iodoacetic acid), precipitated by 1.5 volume of cold acetone, and digested by overnight incubation in a 50-fold molar excess of CNBr over the protein concentration in 70% formic acid.
Antibodies. Several classes of monoclonal antibodies (MAbs) to CT-1, H-LT-1, pDL-2, pDL-3, pDL-5, and pDL-7 used in this study were previously described (5 [5] ) of mouse MAbs (left to right) raised against CT-1, CT-2, H-LT-1, pDL-2, pDL-3, pDL-5, pDL-7, and S-LT with B-subunit antigens (100 ng per spot) CT-B-1, CT-B-2, H-LT-B-1, P-LT-B, pDL-2, pDL-3, pDL-5, and pDL-7 (top to bottom) in native, urea-denatured, CNBr-fragmented, 2-ME-treated, and heated forms. Positive controls for reactivity of CNBr fragments are given in Fig. 4 . sera against synthetic peptides (CTPs) representing different portions of CT-B-1 (8, 9) were kindly provided by Chaim 0. Jacob (Stanford University). Several pre-and postimmunization or pre-and postchallenge sera from adult volunteer cholera vaccinees or volunteer patients with induced cholera (generously provided by James B. Kaper and Myron M. Levine of the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore) were also examined for their reactivities.
CBIB assay procedure. The checkerboard immunoblotting (CBIB) procedure used in this study was described in detail elsewhere (9a). Briefly, antigens, diluted in coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate [pH 9.6]), were immobilized on a solid-phase membrane in parallel lanes by using a Miniblotter apparatus (Miniblotter 45; Immunetics). Coating buffer contained 8 M urea when ureadenatured antigens were used. Nonspecific binding sites were saturated, normally at 4°C overnight, with 5% nonfat dry milk in phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBST). Primary antibodies were then applied in lanes perpendicular to the antigens for 1 to 2 h at room temperature, and the reactions were developed with appropriately labeled secondary antibody and substrate (using the same conditions). After washing, substrate (200 puM) in 10 mM Tris hydrochloride buffer (pH 7.4) and H202 (0.1% [vol/vol]) were added. Reactions were stopped by rinsing with H20. Positive reactions appear as colored squares at the intersection of antibody and antigen, giving a checkerboard appearance to the developed blot. All antibodies were diluted appropriately in PBST containing 0.5% nonfat dry milk. In some assays, the effect of GM, ganglioside (the host cell membrane receptor for the CT-related toxins) treatment of the antigens on their reactivity with antibodies was tested.
In those GM,' assays, after the nonspecific binding sites were blocked, the blot was incubated for 2 h at room temperature in a GM, ganglioside solution (20 ,ug/ml in PBST) and then washed with PBST 3 to 4 times before being reacted with primary antibodies. Some MAbs, such as aCT-1 class VI, aCT-2 classes VI and VII, aHl-LT class I, and apDL-3 class V, were promiscuous and reacted with all of the native antigens tested, indicating the presence of conserved conformational structures in all of the antigens regardless of their amino acid differences. Both aCT-i and aCT-2 class III MAbs reacted with both CT-Bs and in addition with H-LT-B-1 and pDL-7, which all share His-13. They failed to react with other related antigens that have Arg-13 instead of His-13, including (as determined earlier by enzyme-linked immunosorbent assay [5] ) H-LT-B-2, which differs from H-LT-B-1 only in residue 13. His-13 must therefore be involved in the formation of these two epitopes that (Fig. 3 ) must also be either in close proximity to a Gm,-binding site or destroyed or masked by receptor binding. However, from the information available, it is not possible to tell whether these independently derived, identically reactive MAbs are directed against completely identical epitopes.
RESULTS

Reactions of
Reaction of aCT-i class V MAb was limited to those antigens that had Ala-46 instead of Glu-46 (e.g., CT-Bs, H-LT-B, pDL-3, and pDL-5). In a rather similar fashion, apDL-3 class and cxS-LT class IIIA reacted only with H-LT-B and chimeras which had Ala-46 but failed to react with CT-Bs, P-LT-B, or chimeras containing Glu-46. On the other hand, oapDL-2 class I and IA and apDL-7 class III MAbs reacted only with those antigens which had Glu-46 rather than Ala-46 (e.g., P-LT-B, pDL-2, and pDL-7). Interestingly, reactions of some, but not all, of these MAbs were blocked by Gm, (Fig. 3) antibody is blocked by GM, (Fig. 3) . Class IV otH-LT MAb reacted with H-LT-B-1 and pDL-7 but not with other antigens. (This MAb was previously shown not to react with H-LT-B-2 [5] .) The two reactive antigens differ from other antigens by having both Ser-4 and His-13 residues. These two residues can therefore be implied to be necessary for the formation of this epitope, which is affected by GM, binding.
Interestingly, however, cxpDL-7 class V MAb, which is specific for the homologous chimera with Ser-4 and His-13, does not react with H-LT-B-1 and is not blocked by GM,;
other residues in the P-LT-B backbone of pDL-7 are influencing its reactivity. Among the MAbs to chimeric antigens not mentioned earlier is apDL-3 class I, which is weakly reactive with pDL-2 and pDL-3 only. Both of these antigens are distinct from others by having Thr-4 (from its P-LT-B backbone) and Glu-102 residues, which together appear to define this epitope. The reactions of apDL-3 class IIA with H-LT-B, pDL-3, and pDL-5 are similar to, but weaker than, those of class II. Peculiarly, the reactions of aS-LT classes III and IV are stronger in the GM,' assay ( Fig. 3) , which means that the epitope is more exposed upon receptor binding. The reactions of opDL-3 class III MAb are interesting in that it primarily reacts with those antigens that have Glu-102 (H-LT-B, pDL-2, and pDL-3). In contrast to these reactions, apDL-5 class IA reacts only with Lys-102-containing antigens. This phenomenon, within the LT-related antigens, is interesting as changing residue 102 from P-LT-B Lys to H-LT-B Glu results in the formation of some epitopes (e.g., the one recognized by apDL-3 class III) and the disappearance of others (e.g., the ones recognized by apDL-5 class IA). As antibodies to these epitopes react with antigens in a complementary manner, we call them complementary epitopes. Other complementary-type epitopes can also be seen (Fig. 3) , such as those recognized by apDL-2 classes I and IA, as well as apDL-7 class III versus apDL-3 class II and oaS-LT class IIIA.
No purified S-LT antigen was available to include in this study; therefore, reactivities of aS-LT MAbs are defined in terms of their reactions with other related antigens. The oS-LT class II reacted only with H-LT-B, while the class V reaction was only to CT-B-1. This indicates that S-LT probably contains distinct structural elements from both CT-B-1 and H-LT-B. Both class III and class IV reacted only with H-LT-B and pDL-3, with their Ala-46 and Glu-102 distinguishing them from other related antigens. The unique conformation resulting from the presence of these two residues presumably defines the epitopes and may predict residues in S-LT. Figure 3 illustrates the effects of adding GM, ganglioside to the immobilized antigens prior to their reaction with the primary antibodies. As mentioned above, some of the reactions were weakened or obliterated by treatment with GM1, thus implying either that the epitopes are at or near a site which contributes to GM, binding Reactions of hyperimmune polyclonal antisera. In contrast to the observations with MAbs summarized above, polyclonal antisera frequently reacted with denatured forms of the antigen. Shown in Fig. 4 are the reactions of a variety of polyclonal hyperimmune sera against eight B-subunit proteins in various forms. A number of statements can be made about these reactions, and we will cover only a selective few here. First, despite the immunological relatedness of all of the proteins studied, even hyperimmune sera reacted with some degree of specificity and, generally, reactions were stronger with homologous antigen. It will also be noted that individual animals gave different responses to the same antigens. Thus, for example, goat aP-LT reacted very weakly with the CT-Bs and H-LT-B, while goat aH-LT-B reacted better with H-LT-B, pDL-3, pDL-5, and pDL-7. Intact protein conformation was essential for the strongest reactions of these two antisera. The horse aCT-B-1 (equine anti-choleragenoid [2] ) was promiscuous in its activity but reacted most strongly with the CT-Bs and with chimeras with Ala-46 (pDL-3 and pDL-5). Although homologous reactions were strong even with denatured and fragmented antigens, heterologous reactions were weaker with the altered forms of the proteins. Serum samples from four rabbits immunized with CT-B-1, interestingly, appeared to prefer particular denatured forms to the native form of the antigens but with various degrees of reactivity. This was not the case, however, for sera from rabbits immunized with CT-B-2 (which reacted promiscuously with native antigens) or S-LT (which, like goat aH-LT-B, reacted better with H-LT-B, pDL-3, pDL-5, and pDL-7). Neither of these two antisera reacted with CNBr-fragmented antigens.
The rabbit xCTP sera (Fig. 4) (provided earlier by Chaim 0. Jacob [5, 8, 9] ) were raised against synthetic peptides representing portions of CT-B-1. Anti-CTP-1 (raised against residues 8 through 20 of CT-B-1) was very specific for CT-B-1. This suggests that a CT-B-1-specific residue in that region must be definitive for reactivity with this antiserum. As the serum does not react with CT-B-2, and the only difference between CT-B-1 and CT-B-2 in that region is His versus Tyr at position 18, the definitive residue must be His-18. Apparently, this epitope, in the native antigen, is not totally exposed as the native antigen is not reactive. Anti-CTP-3 and otCTP-7, raised against a conserved region of the B-subunit protein (consisting of residues 50 through 64 and 45 through 64, respectively), reacted vigorously with all of the CNBr-fragmented and heat-denatured antigens tested. However, little reactivity was seen with the native antigens in this study. Although this sequence contains, or is part of, a surface epitope, as shown by previous neutralization and protection studies (8) , the antigen(s) is apparently more exposed when the protein is unfolded or, possibly, when it surrounds the A subunit in the holotoxin (unpublished observations).
The mouse antisera used for reactions shown in Fig. 4 were from the same mice as the MAbs described earlier (5) . Apparently, the immune responses in these mice were primarily directed toward the native conformation of anti- Fig. 2 ). Antisera were used at a dilution of 1:1,000, except for oaCT-B-2 (dilution of 1:2,000) and the aCTPs (dilutions of 1:100). Antisera were of goat (G), horse (H), rabbit (R), and mouse (M) origin. Rabbit antisera a, b, c, and d against CT-B-1 were from rabbits 24431, 10836, 10837, and 26923, respectively. gens, as none of the antisera (as was the case with the MAbs) reacted with the fully denatured or fragmented forms of the proteins. Reactions were generally strongest with the homologous antigens, but various degrees of heterologous reactivities were evident. Mouse aCT-1 and aCT-2 reacted only with the CT-B antigens in this study and noticeably more strongly with the homologous B subunit. The mouse antiLTs and anti-chimeras reacted to various extents with the LT family but not with the CT-Bs. The mouse acH-LT reaction was strong only with H-LT-B and the chimeras that have H-LT-B Ala-46 (pDL-3 and pDL-5). The reactions of mouse aP-LT were, on the other hand, stronger with P-LT-B and pDL-5 and pDL-7 that retained the P-LT-B Lys-102. From these results, it is obvious that these mice have focused on the immunological distinctions between the CT and LT groups. As these mice provided the more widely reactive MAbs described above and earlier (5), it also becomes evident that some of those clones represented only a small portion of the entire antibody-producing repertoire.
Reactions of human sera. Humans, like other animals, responded individually to identical immunizations or challenges. Figure 5 summarizes the reactivity of sera from American volunteers prior to and following convalescence from cholera induced by challenges with living virulent V. cholerae of the El Tor biotype. Subjects 4 and 10 exhibited the most vigorous and promiscuous reactions, but it will be noted that an earlier convalescent serum sample from subject 10 was more reactive with the CT-Bs, pDL-2, pDL-3, and pDL-7 and less reactive with H-LT-B, P-LT-B, and pDL-5 than serum from the later bleeding. This same pattern was also given by subjects 3, 8, and 9 and to some extent by subject 6, who very clearly preferred CT-B-2 to CT-B-1. Subjects 1, 2, 5, and 7 had weaker antitoxic responses than did the others. In Fig. 6 , we compare the responses of 10 American volunteers who had received strain CVD 103 (11)-a genetically engineered ctx A-B+ vaccine strain derived from classical wild-type strain 569B Inaba (i.e., CT-B-1)-with those of 10 subjects who had been challenged with virulent El Tor strain N16961. It is immediately obvious that the antitoxic responses were significantly weaker among the recipients of the CVD 103 candidate vaccine strain. It will also be noted that the reactions of the human convalescent sera were largely directed towards conformational determinants, i.e., the reactions were weaker with ureadenatured antigen, and that the reactivity was also reduced by GM, treatment of the antigen, indicating that a proportion of the antibodies were either directed toward the GMlbinding site(s) or the receptor binding altered the protein structure such that some of the epitopes were blocked or destroyed. Reactions of serum samples from subjects 11, 12, 14, and 18 were noticeably stronger with H-LT-B and with chimeras which had CT and H-LT Ala-46 (i.e., pDL-3 and pDL-5). Most of the convalescent sera were more reactive with CT-B-2 than with CT-B-1 (Fig. 5) .
Finally, it may be noted in Fig. 6 that the baseline sera of a number of individuals reacted, weakly but detectably, with the chimeric protein pDL-2, suggesting that these volunteers had previously encountered a related epitope which, among ganglioside. Sera were used at a dilution of 1:50. Symbols: *, subjects 1 through 10 received CVD 103 and subjects 11 through 20 received El Tor N16961; -, prebleeding; +, postchallenge.
------------* X ; (11) . In 1974, we (7) isolated a hypotoxinogenic mutant, M13, of strain 569B which was shortly thereafter found to induce protection against induced cholera in volunteers. The protective effect was of the same magnitude (17) as was reported recently for CVD 103 (11) , which is substantially less than that observed following convalescence from induced cholera in volunteers. In an earlier study in rabbits (15), we were unable to demonstrate significant adherence by strain 569B to the small bowel. Migasena et al. (14) have recently reported that CVD 103-HgR (a further derivative of CVD 103) could be recovered from only 2 of 12 Thai volunteer vaccinees. These observations imply that the relative inability of strain 569B and its derivatives to colonize the small bowel may be reflected in a reduced immune response and suggest that other attenuated strains of V. cholerae would make better vaccines. In such further endeavors, the immunologic differences between CT-1 and CT-2 should be considered.
In conclusion, we have analyzed a variety of immune responses to various forms of CT-related enterotoxin Bsubunit proteins by using a new technique which we call CBIB. This rapid and reproducible technique permits the simultaneous analysis of large numbers of antigen and antibody combinations with minimal amounts of reagents. The results are available within 24 h and are in the form of a permanent record. The observations of this study, although admittedly incomplete, should be considered, together with the earlier results of Jacob et al. (8, 9) with synthetic peptides, in future efforts to construct synthetic peptides which may be used as vaccines against cholera and the CT-related enterotoxic enteropathies. Studies in progress with sequential overlapping synthetic hexapeptides of the B-subunit protein are delineating continuous (sequencerelated) epitopes, which may constitute portions of conformational epitopes described in this work (Kazemi and Finkelstein, unpublished data).
